BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31351411)

  • 1. Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells.
    Guo C; Wang X; Zhang H; Zhi L; Lv T; Li M; Lu C; Zhu W
    Mol Immunol; 2019 Oct; 114():108-113. PubMed ID: 31351411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell.
    Li M; Zhi L; Yin M; Guo C; Zhang H; Lu C; Zhu W
    Biochem Biophys Res Commun; 2020 Mar; 523(3):745-752. PubMed ID: 31952789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY; Mei JZ; Yao KT
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 8. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
    Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
    Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
    Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
    Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells.
    Guo C; Dong M; Wang X; Yu J; Jin X; Cheng S; Cui F; Qian Y; Bao Q; Zhi L; Niu Z; Li M; Zhu W
    Biochem Biophys Res Commun; 2024 May; 710():149918. PubMed ID: 38598902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
    Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
    J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.
    Chang YH; Connolly J; Shimasaki N; Mimura K; Kono K; Campana D
    Cancer Res; 2013 Mar; 73(6):1777-86. PubMed ID: 23302231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
    Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
    Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
    André P; Castriconi R; Espéli M; Anfossi N; Juarez T; Hue S; Conway H; Romagné F; Dondero A; Nanni M; Caillat-Zucman S; Raulet DH; Bottino C; Vivier E; Moretta A; Paul P
    Eur J Immunol; 2004 Apr; 34(4):961-71. PubMed ID: 15048706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells.
    Coudert JD; Zimmer J; Tomasello E; Cebecauer M; Colonna M; Vivier E; Held W
    Blood; 2005 Sep; 106(5):1711-7. PubMed ID: 15886320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
    Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
    J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
    Jachimowicz RD; Fracasso G; Yazaki PJ; Power BE; Borchmann P; Engert A; Hansen HP; Reiners KS; Marie M; von Strandmann EP; Rothe A
    Mol Cancer Ther; 2011 Jun; 10(6):1036-45. PubMed ID: 21525185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.